ARQT
Arcutis Biotherapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$32.07Close
$4.0BMarket cap
$19.50 – $32.8252-week range
Nov 4, 2026Next report · after the close
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 83 · stronger than 83% of stocks over 12 months
- Near its high 2% below its 52-week high
Cautions
- Extended 5.0 ATR above its 50-day average
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
2%
1wk
up 2.8%
price change
1mo
up 21.3%
price change
12-month return
up 29%
market up 11% ·
its own up 16%
F-score
4 / 9
Weak
Altman Z
7.62
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
20.9×
price / book
Earnings yield
down 0.3%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
up 91%
year on year
EPS growth
—
latest quarter
Sales growth
up 59%
latest quarter · -1 pts
ROE
down 9%
return on equity
Free cash margin
down 2%
-$6.3M FCF
D/E
0.57
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- short-term liquidity weakened
- issued more shares
- gross margin narrowed
- profitability improving
- profits backed by cash
- reduced long-term debt
- assets working harder
Trade setup
ATR%
4.1%
$1.31 a day · 2×ATR $29.45
RS
83 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 4.7% over the year, from 118m to 123m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 5, 2026
Results reaction
Aug 5, 2026+2% vs market2 sessions after results
Financials
- Gross 90%
- Net -4%
- Free cash -2%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $3.7M | $59.6M | $196.5M | $376.1M |
| Gross margin | — | — | 80% | 92% | 90% | 90% |
| Operating income | -$136.6M | -$206.5M | -$301.6M | -$241.1M | -$128.4M | -$12.2M |
| Net income | -$135.7M | -$206.4M | -$311.5M | -$262.1M | -$140.0M | -$16.1M |
| Net margin | — | — | -8450% | -440% | -71% | -4% |
| Earnings per share | -$3.80 | -$4.18 | -$5.66 | -$3.78 | -$1.16 | -$0.13 |
| Free cash flow | -$113.4M | -$175.6M | -$258.0M | -$247.5M | -$112.3M | -$6.3M |
| Free cash margin | — | — | -7001% | -415% | -57% | -2% |
| Cash | $65.1M | $96.4M | $53.6M | $88.4M | $71.3M | $42.9M |
| Long-term debt | $0 | $72.3M | $197.8M | $201.8M | $107.2M | $108.0M |
| Shareholders' equity | $270.6M | $297.7M | $209.6M | $88.7M | $157.5M | $189.5M |
| Shares outstanding | 43.34m | 50.26m | 61.04m | 96.79m | 117.85m | 123.33m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 5, 2026 | Quarterly ↗ | Jun 30, 2026 | 36d |
| May 6, 2026 | Quarterly ↗ | Mar 31, 2026 | 36d |
| Feb 25, 2026 | Annual ↗ | Dec 31, 2025 | 56d |
| Oct 28, 2025 | Quarterly ↗ | Sep 30, 2025 | 28d |
| Aug 6, 2025 | Quarterly ↗ | Jun 30, 2025 | 37d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 14, 2024 | Quarterly ↗ | Jun 30, 2024 | 45d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Feb 27, 2024 | Annual ↗ | Dec 31, 2023 | 58d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 28, 2026 | Director or officer change · Regulation FD ↗ |
| Aug 5, 2026 | Results · Director or officer change ↗ |
| Jul 16, 2026 | Director or officer change · Regulation FD ↗ |
| Jun 9, 2026 | Shareholder vote · Other events ↗ |
| May 6, 2026 | Exhibits only ↗ |
| Feb 25, 2026 | Results ↗ |
| Dec 8, 2025 | Director or officer change · Regulation FD ↗ |
| Oct 28, 2025 | Results ↗ |
| Aug 6, 2025 | Results ↗ |
| Jun 17, 2025 | Shareholder vote · Other events ↗ |
| May 6, 2025 | Results ↗ |
| Apr 10, 2025 | Director or officer change · Regulation FD ↗ |